Expedited Reporting Under EU-CTR and FDA Rules
Expedited Reporting Under EU-CTR and FDA Rules Step-by-Step Guide to Expedited Reporting Under EU-CTR and FDA Rules Why Expedited Reporting Matters Expedited reporting of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) is a cornerstone of pharmacovigilance in clinical trials. Regulators worldwide mandate strict timelines so that new safety signals are identified…
Read More “Expedited Reporting Under EU-CTR and FDA Rules” »